IP Library Granted Patent US 11,202,838
Granted Patent B2
US 11,202,838 · App. 15/752,668 · Granted Dec 21, 2021

Substrate delivery of embedded liposomes

Inventors: Srivatsan Kidambi (Lincoln, NE); Stephen L. Hayward (Lincoln, NE)
Assignee: NUtech Ventures
A61K47/6911A61K9/1272A61K31/704A61K47/34A61K47/61C12N15/1135
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,202,838
App. No.
15/752,668
Granted
Dec 21, 2021
Kind
B2
Abstract

This invention relates to compositions useful for localized and sustained release of therapeutic agents, and more particularly to functionalized liposomes embedded in a polyelectrolyte multilayer. Methods of preparing the compositions, methods of treating diseases, devices, and pharmaceutical compositions comprising the compositions are also provided.

Claims (18)

1. A composition comprising:

i) one or more hyaluronic acid conjugated liposomes; and

ii) a polyelectrolyte multilayer;

wherein the hyaluronic acid is covalently bonded to the surface of the liposome;

and wherein the one or more hyaluronic acid conjugated liposomes are deposited onto the polyelectrolyte multilayer.

2. The composition of claim 1 , wherein the polyelectrolyte multilayer comprises one or more independently selected polycationic polymers.

3. The composition of claim 1 , wherein the polyelectrolyte multilayer comprises one or more independently selected polyanionic polymers.

4. The composition of claim 3 , wherein at least one of the polyanionic polymers is poly(sodium styrene sulfonate) (SPS).

5. The composition of claim 1 , wherein the polyelectrolyte multilayer comprises from about 2 to about 10 monolayers of poly-L-lysine (PLL) and from about 2 to about 10 monolayers of poly(sodium styrene sulfonate) (SPS).

6. The composition of claim 1 , wherein the liposome comprises a hydrophilic core and a hydrophobic lipid bilayer.

7. The composition of claim 1 , wherein the liposome further comprises one or more therapeutic agents.

8. The composition of claim 6 , wherein each of the therapeutic agents is independently localized in the hydrophilic core or hydrophobic lipid bilayer of the liposome.

9. The composition of claim 1 , wherein the liposome further comprises a fluorescently tagged lipid.

10. The composition of claim 1 , wherein the liposome further comprises a targeting moiety.

11. The composition of claim 10 , wherein the targeting moiety is conjugated to the hyaluronic acid.

12. The composition of claim 1 , further comprising an additional polyelectrolyte multilayer.

13. The composition of claim 1 , further comprising a substrate selected from the group consisting of a medical device, a tablet, a capsule, a bandage, a gel, and a nanoparticle.

14. The composition of claim 2 , wherein at least one of the polycationic polymers is poly-L-lysine (PLL).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: KIDAMBI, SRIVATSAN; HAYWARD, STEPHEN L.
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 050054/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2018
From: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
To: NUTECH VENTURES
Reel/Frame 045495/0149 →
Continuity (2)
Provisional Application 62205473 · Aug 14, 2015
Related Publication 20190030184A1 · Jan 31, 2019